Vaginitides, STIs, PID Flashcards
A 21 yo G0 LMP 1 week ago complains of a foul smelling, watery, slightly pruritic vaginal discharge for 3 weeks. She denies douching. She also states she does not use condoms with her male partner, with whom she has been having sex for about a month.
You diagnose your patient with bacterial vaginosis, and reassure her that this is not classified as a sexually transmitted infection. You prescribe metronidazole 500 mg PO BID x 1 week. She visits you two months later for a routine visit and tells you that the infection got much better very quickly.
normal vaginal discharge in pts of reproductive age
-White, yellow or clear
-May change through menstrual cycle
-Nonpruritic
-Non-malodorous
-Not associated with any kind of pain
vaginal ecology
-reproductive age- pH of 3.5-4.5
-Lactobacillus spp. are produced in an estrogenized vagina
-Lactobacilli maintain this acidic pH by producing H2O2
MC vaginitides
-abnormal vaginal discharge:
-20-50% have bacterial vaginosis
-15-40% have vulvovaginal candidiasis
-5-35% have trichomoniasis
-Of these, only trichomoniasis is considered to be a sexually transmitted disease (STI)
-These can also coexist among each other, and/or with STIs
prevalence and pathophysiology of bacterial vaginosis (BV)
-Prevalence: about 29.2% worldwide
-Due to an unknown event that changes the microbial flora of the vagina,
-Lactobacilli decline
-Facultative and strict anaerobes predominate
-Many associated organisms, including but not limited to:
-Atopobium vaginae
-Gardnerella vaginalis
-Bacteroides spp
-Mobiluncus spp
-Prevotella spp
-Porphyromonas spp
possible pathophysiology of BV: other etiologies
-An intravaginal event or exposure triggers the change in flora
-Vaginal exposure to:
-Semen
-Tampons
-Douching
-Could BV be an STI?
-Condoms seem to prevent BV
-Circumcision in male partners reduces incidence of BV in female partners by 40-60%
-Gardnerella vaginalis was thought to be a true pathogen in the past
-It is capable of forming a biofilm that can reduce the number of lactobacilli and that can increase BVAB
hx of the pt with BV
-Length of symptoms
-History of similar episodes
-Sexual history- new partner?
-Use of sanitary products (douching, soaps, feminine hygiene)
-Relationship of symptoms to menses
PE in BV and dx
-Thin, homogenous, gray to white discharge
-Fishy odor
-Pruritus
-Dysuria
-pt feels systemically well
-Dx:
-Amsel’s criteria:
-Thin, gray, homogenous vaginal D/C
-Presence of clue cells (>4 per HPF) seen on wet mount -> Clue cells: epithelial cells whose borders are obscured by adherent bacteria
-+KOH whiff test
-Vaginal pH>4.5!
-Gold standard: Gram stain with Nugent scoring
-DNA hybridization and detection of vaginal fluid sialidase are most common tests performed today
-Do not treat based only on Pap results suggesting BV
-tests for:
-Lactobacillus crispatus
-Lactobacillus jensenii
-Gardnerella vaginalis
-Atopobium vaginae
-BVAB-2
-Megasphera 1
BV tx
-Metronidazole
-Oral: !metronidazole 500 mg orally twice daily x 7 days; preferred initial therapy!
-Topical: metronidazole 0.75% vaginal gel, 1 applicator intravaginally once daily x 5 days
-Clindamycin
-Vaginal: clindamycin cream 2%, 1 applicator intravaginally at bedtime x 7 days
-Alternatives: (dont need to know)
-Secnidazole - 2 gm orally in a single dose
-Tinidazole- 2 gm orally once daily x 2 days, OR 1 gm orally once daily x 5 days
-Clindamycin- 300 mg orally twice daily x 7 days, OR Clindamycin ovules, 100 mg intravaginally once at bedtime x 3 days
BV sequelae
-Complications of pregnancy
-Prelabor rupture of membranes
-Premature prelabor rupture of membranes
-Complications of gynecologic surgery in which the vagina is entered
-Cellulitis or abscess formation
-HIV transmission to male partners
-Increased risk of infection with genital herpes, gonorrhea and chlamydia
management of recurrent BV
-30% of pts treated for BV will have a recurrence within 1 month
-58% will have recurrence within 1 year
-Research indicates that G. vaginalis and other anaerobes form a biofilm that persists even after treatment
-Risk factors for recurrent BV:
-Douching
-Inability to restore lactobacilli to vaginal flora
-Regimen 1: metronidazole vaginal gel 0.75% 1 applicator intravaginally once daily x 10 days, then 2x/week x 6mo
-Regimen 2: Boric acid vaginal suppositories 600 mg intravaginally once daily at HS x 3 weeks AND simultaneously prescribe a standard regimen
-Regimen 3: metronidazole 2 gm orally and fluconazole 150 mg orally both administered monthly AFTER completion of a standard regimen
-In AFAB pts who have sex with AFAB people: Tx partner if sx
-In AFAB patients who have sex with AMAB people:
-Encourage condom use
-Consider circumcision
-No indication at present for treatment of AMAB people
-Evidence is mixed regarding the efficacy of probiotics
-Vaginal microbiome transplantation trials have demonstrated remission of intractable BV in a small group of patients -> More investigation is needed
prevalence and patho of vulvovaginal candidiasis (VVC)
-70% of pts will ahve VVC at least once
-caused by overgrowth of Candida spp. often due to:
-Recent antibiotic use
-Pregnancy
-Hormonal contraceptive use
-Uncontrolled diabetes mellitus
-Sexual activity
-HIV infection
-Steroid use
Candida species responsible for VVC
-Candida albicans (>70%)
-Candida glabrata
-Candida guilliermondii
-Candida krusei
-Candida parapsilosis
-Candida tropicalis
hx of pt with VVC
-intense pruritus of vulva and vagina
-white curdlike discharge
-dysuria
-dyspareunia
PE and Dx: vulvovaginal candidiasis
-White curdlike discharge
-Hyperemic vulvovaginal tissues
-Excoriations of vulva and vagina
-pruritus, dysuria, dyspareunia
-pH < 4.5
-Dx:
-!Should not be based on hx and PE alone
-Include one of the following:
-Microscopy with visualization of pseudohyphae, hyphae, or spores
-Laboratory data- Culture, DNA probe technology, or PCR testing
-Do not treat based alone on Pap smear that identified fungal organisms
-Do not treat presumptively without clinical evaluations
-Pseudohyphae of C. albicans seen on wet mount
-PCR: 97% sensitive, 93% specific for: Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsilosis, Candida krusei
uncomplicated vs complicated VVC
-UNCOMPLICATED VVC:
-infrequent episodes
-mild-moderate sx or findings
-infection with candida albicans
-no hx of compromised immune system
-COMPLICATED VVC:
-4 or more episodes annually
-severe symtpoms
-infection with non-C. albicans organism
-hx of compromised immune system
over the counter tx options for uncomplicated VVC
-Clotrimazole:
-1% cream, 5 gm intravaginally once daily x 7-14 days
-2% cream, 5 gm intravaginally once daily x 3 days
-Tioconazole 6.5% ointment, 5 gm intravaginally once
-miconazole creams:
-2% cream, 5 gm intravaginally once daily x 7 days
-4% cream, 5 gm intravaginally once daily x 3 days
-miconazole suppositories:
-100 mg, 1 suppository intravaginally at bedtime x 7 days
-200 mg, 1 suppository intravaginally at bedtime x 3 days
-1200 mg, 1 suppository intravaginally at bedtime x 1 day
-Topical OTC imidazoles are highly effective BUT approx 33% dx correctly with VVC
-Correct dx include BV, contact dermatitis, and trichomoniasis
-Pts may confuse OTC imidazole preparations with:
-Vaginal anti-itch preparations
-Homeopathic preparations
prescription only tx for uncomplicated VVC
-Fluconazole 150 mg, 1 tablet orally x 1 dose
-Butoconazole 2% cream, 5 gm intravaginally once
-Terconazole 0.4% cream, 5 gm intravaginally at bedtime x 7 days
-Terconazole 0.8% cream, 5 gm intravaginally at bedtime x 3 days
-Terconazole 80 mg, 1 suppository intravaginally at bedtime x 3 days
-terconazole -> Candida glabrata
management of complicated VVC: current C. albicans infections
-RF:
-Immunosuppression
-Diabetes mellitus
-Antibiotic use
-Recurrent bacterial vaginosis
-At least 3 episodes in 12 month period
-Must be documented with lab data
-Culture is the preferred means of diagnosis -> Includes identification of Candida spp and sensitivities
-MC species:
-Candida glabrata
-Candida parapsilosis
-Candida tropicalis
-Candida lusitaniae
-Candida krusei
-Obtain culture for identification of species and sensitivities
-Fluconazole 150 mg, 1 tab orally every 72 hours x 3 doses, THEN
-Fluconazole 150 mg, 1 tab orally every week x 6 months -> 50% of pts relapse within 6mo of completion of suppressive therapy
tx of complicated VVC: non-C. albicans VVC
-Boric acid 600 mg suppository, 1 intravaginally at bedtime, for a minimum of 14 days
-Caution pts about avoiding accidental exposure to children or animals
-Flucytosine 5 gm intravaginally at bedtime x 14 days (for C. glabrata)
-Current cost is estimated between $182-$2000 per day
management of complicated VVC: severe sx
-marked by fissures, edema, erosion
-prolonged intravaginal agent like terconazole x 10-14 days, OR
-Oral fluconazole (150mg or 200mg) taken daily every 72 hours x 3 doses
prevalence and patho of trichomoniasis
-Approx 276 million cases worldwide annually
-About 3-5 million annual cases in the United States
-Caused by Trichomonas vaginalis, a flagellated protozoan
-A sexually transmitted infection (STI) -> Fomite transmission is theoretically possible but is generally unlikely
-Adherence of the organism to epithelial cells and parasite-mediated apoptosis results in lysis of the cell and erosion of the epithelium
-In the female lower genital tract, T. vaginalis may be able to persist due to the presence of iron due to menstrual blood
risk factors of trichomoniasis
-MC in young pts of reproductive age
-Risk factors include:
-Oral contraceptive use
-Low socioeconomic status
-Smoking
-Non-monogamous relationships
-One of the only STIs that causes more symptoms in AFAB patients than in AMAB people
-Asymptomatic in 25-50% of all cisgender women
hx of pt with trichomoniasis
-vaginal pruritus
-vaginal pain
-dysuria
-dyspareunia
-frothy!!! vaginal discharge
-worsened infection with menses
-abdominopelvic pain in assoc with PID